Stefanie Schalm

Stefanie Schalm has over 20 years of experience in the biopharmaceutical industry, with a focus on program biology, oncology, and rare monogenetic diseases. Stefanie is currently working as the VP of Program Biology at Entact Bio since June 2023. Prior to that, they served as the Senior Director of Oncology at Kymera Therapeutics from September 2021 to May 2023. From February 2020 to September 2021, Stefanie held the role of Director of Biology at Blueprint Medicines, where they co-led the EGFR triple mutant inhibitor program and served as the biology lead for GAVRETO™ (pralsetinib). Stefanie also served as a Principal Scientist, Senior Scientist II, and Senior Scientist at Blueprint Medicines from 2013 to 2020. Stefanie started their career as a Scientist at Agios Pharmaceuticals from May 2010 to March 2013. Stefanie completed their postdoctoral research at Harvard University from October 2003 to April 2010.

Stefanie Schalm obtained a Ph.D. in Biochemistry from Freie Universität Berlin, completing their studies from 1999 to 2003.